Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC Update - February 2015

The Scottish Medicines Consortium (SMC) has issued its monthly advice on newly licensed medicines.

Colestilan (BindRen®) has been rejected for the treatment of hyperphosphataemia in adult patients with chronic kidney disease (CKD) stage 5 receiving haemodialysis or peritoneal dialysis. Comparative date with others similar agents did not demonstrate non-inferiority conclusively. The manufacturer did not present a sufficiently robust clinical and economic analysis to gain acceptance.

Umeclidinium / Vilanterol (Anoro®) has been accepted for use as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease. Two randomised controlled studies demonstrated improved lung function compared with an inhaled long-acting muscarinic antagonist and indirect comparisons demonstrated comparable efficacy with similar drug combinations.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC Update - February 2015' on Email Share 'SMC Update - February 2015' on Delicious Share 'SMC Update - February 2015' on Digg Share 'SMC Update - February 2015' on Facebook Share 'SMC Update - February 2015' on reddit Share 'SMC Update - February 2015' on StumbleUpon Share 'SMC Update - February 2015' on Twitter

atomic-wealth

No Comments to “SMC Update - February 2015”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.

atomic-wealth
fond-illness
summer